Recombinant Biotinylated Human EGFRvIII, Avi Tag (Avitag™), His tag, 25µg

Background
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

Source
Recombinant Biotinylated Human EGFRvIII, His,Avitag(EGR-H82E0) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Ser 378 (Accession # NP_001333870.1).
Predicted N-terminus: Leu 25

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 42.2 kDa. The protein migrates as 60-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Plasma ctDNA liquid biopsy of IDH1, TERTp, and EGFRvIII mutations in glioma"
Jones, Nguyen, Wong et al
Neurooncol Adv (2024) 6 (1), vdae027
(2) "Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying EGFR"
Spinelli, Adnani, Meehan et al
Nat Commun (2024) 15 (1), 2865
(3) "EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models"
Álvarez-Vázquez, San-Segundo, Cerveró-García et al
Neuro Oncol (2024)
Showing 1-3 of 1152 papers.